antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»antibiotics-348Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSАнтимикробная активность бактериоцина S760, продуцируемого штаммом Enterococcus faecium LWP760Antimicrobial Activity of Bacteriocin S760 Produced by Enterococcus faecium Strain LWP760СветочЭ. А.SvetochE. A.noemail@neicon.ruЕруслановБ. В.EruslanovB. V.noemail@neicon.ruЛевчукВ. П.LevchukV. P.noemail@neicon.ruМицевичЕ. В.MitsevichE. V.noemail@neicon.ruМицевичИ. П.MitsevichI. P.noemail@neicon.ruКовалевЮ. Н.KovalevYU. N.noemail@neicon.ruФурсоваН. К.FursovaN. K.noemail@neicon.ruТеймуразовМ. Г.TeimurazovM. G.noemail@neicon.ruСтепаншинЮ. Г.StepanshinYU. G.noemail@neicon.ruВолодинаЛ. И.VolodinaL. I.noemail@neicon.ruДятловИ. А.DyatlovI. A.noemail@neicon.ruГосударственный научный центр прикладной микробиологии и биотехнологии Роспотребнадзора, ОболенскРоссияState Research Center for Applied Microbiology and Biotechnology, Rospotrebnadzor, ObolenskRussian Federation201113052020561-239Copyright © ООО «Издательство ОКИ», 20202020ООО «Издательство ОКИ»ООО «Издательство ОКИ»https://www.antibiotics-chemotherapy.ru/jour/about/submissions#copyrightNoticehttps://www.antibiotics-chemotherapy.ru/jour/article/view/348

Изучена антимикробная активность бактериоцина энтероцина S760 - катионного, гидрофобного, термоустойчивого пептида с молекулярной массой 5,5 кДа и pI=9,8, продуцируемого штаммом Enterococcus faecium LWP760. Показано, что энтероцин S760 подавляет in vitro рост грамположительных и грамотрицательных бактерий 25 видов как чувствительных, так и устойчивых к антибиотикам. МПК энтероцина S760 для Escherichia coli O157:H7, Salmonella typhimurium, Salmonella enteritidis, Campylobacter jejuni, Yersinia enterocolitica, Yersinia pseudotuberculosis, Listeria monocytogenes и Clostridium perfringens - основных возбудителей пищевых инфекций - колебалась в пределах 0,05-1,6 мг/л; для Streptococcus pyogenes, Streptococcus pneumoniae и Corynebacterium diphtheriae - в пределах 0,4-1,6 мг/л. Энтероцин S760 был активен против антибиотикоустойчивых штаммов Staphylococcus aureus, Enterobacter cloacae, Acinetobacter baumannii (МПК 0,05-3 мг/л), Klebsiella pneumoniae (МПК 6 мг/л), Pseudomonas aeruginosa (МПК 0,4-25 мг/л), а также против грибов Candida albicans, Candida krusei и Aspergillus niger (МПК 0,1-0,2 мг/л). Энтероцин S760 рассматривается как новое перспективное антимикробное средство для использования в медицине, ветеринарии и пищевой промышленности.

Antimicrobial activity of bacteriocin S760 (enterocin) produced by Enterococcus faecium strain LWP760 was studied. Bacteriocin S760 is a cationic, hydrophobic, and heat stable peptide with the molecular weight of 5.5 kDa and pI of 9.8. Enterocin S760 is shown to inhibit in vitro the growth both of sensitive and resistant to antibacterials gramnegative and grampositive bacteria of 25 species. MICs of the bacteriocin S760 vary between 0.05-1.6 mg/l for Escherichia coli O157:H7, Salmonella typhimurium, Salmonella enteritidis, Campylobacter jejuni, Yersinia enterocolitica, Yersinia pseudotuberculosis, Listeria monocytogenes and Clostridium perfringens, that are main food-borne pathogens, and from 0.4-1.6 mg/l for Streptococcus pyogenes, Streptococcus pneumoniae and Corynebacterium diphteriae. It is also active against antibioticresistant strains of Staphylococcus aureus, Enterobacter cloacae, Acinetobacter baumannii (with MICs of 0.05-3 mg/l), Klebsiella pneumoniae (with MICs of 6 mg/l), Pseudomonas aeruginosa (with MICs of 0.4-25 mg/l), as well against fungi belonging to species of Candida albicans, Candida krusei and Aspergillus niger (with MICs of 0.1-0.2 mg/l). Enterocin S760 is a novel antimicrobial agents useful in medicine, veterinary and food industry.

бактериоцинантимикробная активностьальтернатива антибиотикамbacteriocinantimicrobial activityalternative for antibioticsReferencesPeterson D.L., Rossi F. et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 6: 965-973.Peterson D.L., Rossi F. et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 6: 965-973.Страчунский Л.С. β-лактамазы расширенного спектра - быстро растущая и плохо осознаваемая угроза. Клин. микробиол. антимикроб химиотер. 2005; 7: 1: 92-96.Страчунский Л.С. β-лактамазы расширенного спектра - быстро растущая и плохо осознаваемая угроза. Клин. микробиол. антимикроб химиотер. 2005; 7: 1: 92-96.Chopra I., Schofield C., Everett M. et al. Treatment of healthcare-associated infection caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008; 8: 2: 133-139.Chopra I., Schofield C., Everett M. et al. Treatment of healthcare-associated infection caused by Gram-negative bacteria: a consensus statement. Lancet Infect Dis 2008; 8: 2: 133-139.Ennahar S., Sashihara T., Sonomoto K. et al. Class lia bacteriocins: biosynthesis, structure, and activity. FEMS Microbiol Rev 2000; 24: 1: 85-106.Ennahar S., Sashihara T., Sonomoto K. et al. Class lia bacteriocins: biosynthesis, structure, and activity. FEMS Microbiol Rev 2000; 24: 1: 85-106.Popaganni M. Ribosomally synthezed peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 6: 465-499.Popaganni M. Ribosomally synthezed peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 2003; 21: 6: 465-499.Pascual L.M., Dariele M.B., Giordano W. et al. Purification and partial characterization of novel bacteriocin L23 produced by Lactobacillus fer-mentum L23. Curr Microbiol 2008; 56: 4: 97-402.Pascual L.M., Dariele M.B., Giordano W. et al. Purification and partial characterization of novel bacteriocin L23 produced by Lactobacillus fer-mentum L23. Curr Microbiol 2008; 56: 4: 97-402.Svetoch E., Eruslanov B., Perelygin V. et al. Diverse antimicrobial killing by Enterococcus faecium E 50-52 bacteriocin. J Agric Food Chem 2008; 56: 6: 1942-1948.Svetoch E., Eruslanov B., Perelygin V. et al. Diverse antimicrobial killing by Enterococcus faecium E 50-52 bacteriocin. J Agric Food Chem 2008; 56: 6: 1942-1948.Galves A., Abriouel H., Benomar N., Lucas R. Microbial antagonists to food-borne pathogens and biocontrol. Curr Opin Biotechnol 2010; 21: 2: 142-148.Galves A., Abriouel H., Benomar N., Lucas R. Microbial antagonists to food-borne pathogens and biocontrol. Curr Opin Biotechnol 2010; 21: 2: 142-148.Kaewsrichan J., Peeyananjarassri K., Kongprasertkit J. Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. FEMS Immunol Med Microbiol 2006; 48: 1: 75-83.Kaewsrichan J., Peeyananjarassri K., Kongprasertkit J. Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. FEMS Immunol Med Microbiol 2006; 48: 1: 75-83.Cornut G., Fortin C., Soulieres D. Antineoplastic properties of bactiocins: revisiting potential active agents. Am J Clin Oncol 2008; 31: 4: 399-404.Cornut G., Fortin C., Soulieres D. Antineoplastic properties of bactiocins: revisiting potential active agents. Am J Clin Oncol 2008; 31: 4: 399-404.Todorov S.D., Dicks L.M.T. Partial characterization of bacteriocins produced by four lactic acid bacteria isolated from regional South African barley beer. Annals of Microbiol 2004; 54: 4: 403-413.Todorov S.D., Dicks L.M.T. Partial characterization of bacteriocins produced by four lactic acid bacteria isolated from regional South African barley beer. Annals of Microbiol 2004; 54: 4: 403-413.Sang Y., Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev 2008; 9: 2: 227-235.Sang Y., Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim Health Res Rev 2008; 9: 2: 227-235.Piper C., Draper L.A., Cotter P.D. et al. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009; 64: 3: 546-551.Piper C., Draper L.A., Cotter P.D. et al. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother 2009; 64: 3: 546-551.Svetoch E.A., Eruslanov B.V., Kovalev Y.N. et al. Antimicrobial Activities of Bacteriocin E 50-52 and B 602 Against Antibiotic-Resistant Strains Involved in Nosocomial infections. Probiotic Antimicrob Prot 2009; 1: 2: 136-142.Svetoch E.A., Eruslanov B.V., Kovalev Y.N. et al. Antimicrobial Activities of Bacteriocin E 50-52 and B 602 Against Antibiotic-Resistant Strains Involved in Nosocomial infections. Probiotic Antimicrob Prot 2009; 1: 2: 136-142.Lawton E.M., Ross R.P., Hill C. et al. Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 2007; 7: 12: 1236-1247.Lawton E.M., Ross R.P., Hill C. et al. Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem 2007; 7: 12: 1236-1247.Щетинин Е.В. Полимиксины - новый взгляд на известные антибиотики. Клин. Микробиол. Антимикроб. Химиотер. 2000; 7: 3: 68-73.Щетинин Е.В. Полимиксины - новый взгляд на известные антибиотики. Клин. Микробиол. Антимикроб. Химиотер. 2000; 7: 3: 68-73.Riley M. Research and Applications in Bacteriocins / Ed. M.F. Riley, O. Gillor. Horizon Bioscience, 2007; 153-180.Riley M. Research and Applications in Bacteriocins / Ed. M.F. Riley, O. Gillor. Horizon Bioscience, 2007; 153-180.Duc le H., Hong T.M., Barbosa J.A. et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70: 4: 2161-2171.Duc le H., Hong T.M., Barbosa J.A. et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004; 70: 4: 2161-2171.Line J., Svetoch E.A., Eruslanov B.V. et al. Isolation and purification of enterocin E-760 with broad antimicrobial activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2008; 52: 3: 1094-1100.Line J., Svetoch E.A., Eruslanov B.V. et al. Isolation and purification of enterocin E-760 with broad antimicrobial activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2008; 52: 3: 1094-1100.Klaenhammer T.R. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 1993; 12: 1-3: 39-85.Klaenhammer T.R. Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol Rev 1993; 12: 1-3: 39-85.Светоч Э.A., Ерусланов Б.В., Левчук В.П. и др. Новый класс антимикробных препаратов - бактериоцины и их применение для борьбы с кампилобактериозом и сальмонеллёзом бройлерной птицы. III Международный Ветеринарный Конгресс по Птицеводству. М.: 2007; 205-212.Светоч Э.A., Ерусланов Б.В., Левчук В.П. и др. Новый класс антимикробных препаратов - бактериоцины и их применение для борьбы с кампилобактериозом и сальмонеллёзом бройлерной птицы. III Международный Ветеринарный Конгресс по Птицеводству. М.: 2007; 205-212.Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». Утверждены Главным государственным санитарным врачом РФ Г.Г. Онищенко 04.03.2004 г.Методические указания МУК 4.2.1890-04 «Определение чувствительности микроорганизмов к антибактериальным препаратам». Утверждены Главным государственным санитарным врачом РФ Г.Г. Онищенко 04.03.2004 г.NCCLS/CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Document M7-A5. Clinical and Laboratory Standards Institute, Wayne, PA.NCCLS/CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Document M7-A5. Clinical and Laboratory Standards Institute, Wayne, PA.Joerger R.D. Alternatives to antibiotics: Bacteriocins, Antimicrobial Peptides and Bacteriophages. Poultry Science 2003; 82: 4: 640-647.Joerger R.D. Alternatives to antibiotics: Bacteriocins, Antimicrobial Peptides and Bacteriophages. Poultry Science 2003; 82: 4: 640-647.Kruszewka D., Sahl H., Bierbaum G. et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 2004; 54: 3: 648-653.Kruszewka D., Sahl H., Bierbaum G. et al. Mersacidin eradicates methicillin-resistant Staphylococcus aureus (MRSA) in a mouse rhinitis model. J Antimicrob Chemother 2004; 54: 3: 648-653.Mota-Meira M., Morency H., Lavoie M.C. In vivo activity of mutacin B-Ny266. J Antimicrob Chemother 2005; 56: 5: 869-871.Mota-Meira M., Morency H., Lavoie M.C. In vivo activity of mutacin B-Ny266. J Antimicrob Chemother 2005; 56: 5: 869-871.Sit C.S., Videras J.C. Aproaches to the discovery of new antibacterial agents based on bacteriocins. Biochem Cell Biol 2008; 86: 116-123.Sit C.S., Videras J.C. Aproaches to the discovery of new antibacterial agents based on bacteriocins. Biochem Cell Biol 2008; 86: 116-123.Sosunov V., Mischenko V., Eruslanov B. et al. Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother 2007; 59: 5: 919-925.Sosunov V., Mischenko V., Eruslanov B. et al. Antimycobacterial activity of bacteriocins and their complexes with liposomes. J Antimicrob Chemother 2007; 59: 5: 919-925.Lertcanawanichakul M. Isolation and Selection of Anti-Candida albicans Producing Lactic Acid Bacteria. Walailak J Sci Tech 2005; 2: 2: 179-187.Lertcanawanichakul M. Isolation and Selection of Anti-Candida albicans Producing Lactic Acid Bacteria. Walailak J Sci Tech 2005; 2: 2: 179-187.

The authors declare that there are no conflicts of interest present.